[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"takayasu-arteritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:takayasu-arteritis":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,59,91,136,161,188,227,257,277,303,328,365,388,407,432,457],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":37,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100598885","eacvi-study-on-multimodality-cardiovascular-imaging-of-inflammatory-cardiovascular-diseases-100598885",false,"NCT07077304","EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases","EACVI-INFLAME","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ability to provide informed non-opposition\n3. Referred for a CMR and\u002For nuclear imaging exam\n\nAND a suspicion of one of the following ICARDs :\n\n1. Suspected Myocarditis (acute or chronic, and whatever the aetiologies)\n2. Suspected Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA)\n3. Suspected Tako-Tsubo\n4. Suspected Pericarditis (acute or chronic, and whatever the aetiologies)\n5. Suspected Connective tissue disease with cardiovascular involvement:\n\n   * Systemic sclerosis\n   * Systemic lupus erythematosus\n   * Antiphospholipid syndrome\n   * Idiopathic inflammatory myopathies\n   * Rheumatoid arthritis, spondylarthritis\n6. Suspected Vasculitis with cardiovascular involvement:\n\n   * Small-vessel vasculitis (ANCA…)\n   * Large vessel vasculitis (Behcet disease, Takayasu…)\n7. Suspected Inflammatory disease with cardiovascular involvement:\n\n   * Sarcoidosis\n   * Still disease\n\nExclusion Criteria:\n\n1. Inability to provide non-opposition\n2. History of heart transplant","ALL","18 Years",{"count":19,"type":20},5000,"ESTIMATED","OBSERVATIONAL","Inflammatory Cardiovascular Diseases and Autoimmune Rheumatic Diseases (ICARDs) encompass cardiovascular involvement in connective tissue diseases, vasculitis, and primary inflammatory cardiac processes affecting all layers of the heart. ICARDs are associated with increased cardiovascular morbidity and mortality, independently of traditional risk factors, via multiple pathophysiological mechanisms.\n\nDiagnosis and prognosis are challenged by the heterogeneity of clinical presentations. Multimodality cardiovascular imaging - including cardiovascular magnetic resonance (CMR), transthoracic echocardiography, and positron emission tomography (PET) - plays a central role in detecting and characterizing inflammatory involvement, and may offer prognostic insights.\n\nGiven the limited data on the diagnostic and prognostic utility of these imaging modalities in ICARDs, the EACVI-INFLAME study aims to assess the prevalence of confirmed cardiovascular involvement in patients with suspected or established ICARDs undergoing CMR and\u002For cardiac PET in a multicentric international cohort.",[24,25,26,27,28,29,30,31,32,33,34,35,36],"Myocarditis","ANCA Associated Vasculitis","Pericarditis","Systemic Sclerosis","Systemic Lupus Erythematosus","Idiopathic Inflammatory Myopathies","Rheumatoid Arthritis","Spondylarthritis","Behcet Disease","Takayasu Arteritis","Sarcoidosis","Still Disease","Tako Tsubo Cardiomyopathy",[38,39,40,41,42,43,44,45],"Cardiovascular disease","Auto-immune disease","Auto-inflammatory disease","Rheumatic disease","CMR","PET","multimodality imaging","ICARD","RECRUITING","2026-06-03",{"date":49,"type":50},"2026-06-05","ACTUAL",{"date":52,"type":50},"2025-11-19",{"date":54,"type":20},"2028-10-30",{"name":56,"class":57},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100639991","long-axial-field-of-view-lafov-18ffdg-petct-imaging-in-large-vessel-vasculitis-lvv-protocol-optimisation-study-100639991","NCT07628075","Long-Axial Field of View (LAFOV) [18F]FDG PET\u002FCT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.","LAVA-FLOW","Inclusion Criteria LVV Patients:\n\n* ≥18 years of age\n* Newly diagnosed LVV (based on the 2022 American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) classification criteria or from a definite diagnosis of LVV on standard of care imaging)\n* WHO performance status 0-2\n* The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained\n* eGFR of ≥30 (mL\u002Fmin\u002F1.73m2) within 3 months of \\[18F\\]FDG injection in subjects who have a history of renal impairment, renal disease, renal transplant or diabetes\n\nExclusion Criteria LVV Patients:\n\n* The subject is pregnant or lactating\n* Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure\n* History of allergy to iodinated contrast\n* Commencement of steroids \\> 7 days prior to administration of the radiotracer\n* Poorly controlled diabetic with a blood glucose \\>11mmol\u002FL\n* Evidence of a significant medical condition or laboratory finding which, in the opinion of the Investigator, makes it undesirable for the patient to participate in the trial.\n\nInclusion Criteria Healthy Volunteers:\n\n* Three subjects ≥18 years of age that are also \\\u003C 50 years old and three subjects ≥50 years of age\n* WHO performance status 0-2\n* The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained\n\nExclusion Criteria Healthy Volunteers:\n\n* The subject is pregnant or lactating\n* Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure\n* Participants with any contra-indication to MRI\n* Known allergy to gadolinium-based contrast agents\n* History of smoking\n* History or current diagnosis of the following medical conditions:\n* Diabetes Mellitus\n* Chronic Kidney Disease\n* Atrial Fibrillation\n* Migraines\n* Rheumatoid Arthritis\n* Systemic Lupus Erythematosus (SLE)\n* Historic or current prescription of the following medications:\n* Any blood pressure medication\n* Any antipsychotic medication\n* Steroids\n* Weight of ≥75Kg (in order to keep the radiation dose \\\u003C10mSV for HV)\n* Evidence of any significant medical condition which, in the opinion of the Investigator, makes it undesirable for the HV to participate in the trial\n* Participants that have undergone any imaging investigation that exposes them to radiation within the previous 12 months",true,{"count":68,"type":20},18,"INTERVENTIONAL",[71],"NA","Large vessel vasculitis (LVV) is an autoimmune inflammatory disorder affecting the major arteries of the body. The diagnosis and monitoring this condition can be challenging, as patients often present with symptoms that are unclear, and the diagnostic criteria currently used are varied. Accurate diagnosis is essential because it helps to tailor the treatment to each patient. Some treatments, such as steroids and immunosuppressive medications, can have significant side effects, so they need to be used carefully and only when truly needed.\n\nAn \\[18F\\]FDG Positron Emission Tomography\u002FComputed Tomography (PET\u002FCT) involves the injection of a small amount of radiolabelled sugar, which assesses glucose metabolism within the body. \\[18F\\]FDG PET\u002FCT is already used by the NHS to detect inflammation within the vessel walls and diagnose LVV. Current diagnostic criteria for LVV largely rely on visual assessment by a radiologist. This approach therefore has limitations and may not fully capture changes in the levels of inflammation over time.\n\nA new generation of scanners, known as Long Axial Field-of-View (LAFOV)-PET\u002FCT or Total Body PET, are currently transforming what is possible in the field of medical imaging. These LAFOV-PET\u002FCT scanners have new digital detectors that are more sensitive, produce sharper images, and can scan the entire body rapidly. This offers several potential advantages for patients with LVV, including the clearer detection of vessel wall inflammation, the ability to administer lower doses of the radiolabelled sugar (\\[18F\\]FDG), and the ability to take repeated pictures over time to measure subtle changes in blood flow and inflammation. Patients receiving a routine NHS \\[18F\\]FDG PET\u002FCT scan for LVV are typically scanned 60 minutes after injection of the radiotracer using a standard PET\u002FCT. Another benefit of LAFOV-PET\u002FCT scanners is their ability to assess the amount of the radiolabelled sugar taken up by the whole body almost as soon as it is injected which could give important additional information.\n\nAs part of the LAVA-FLOW study we are planning to combine LAFOV-PET\u002FCT with a CT Angiogram (CTA) in patients with LVV. A CTA is a scan that shows doctors what your blood vessels look like. It involves the injection of a dye into a vein that makes your blood vessels visible, highlighting vessel wall inflammation and vessel wall narrowing. This combination of LAFOV-PET\u002FCT and CTA therefore has the potential to give a much more detailed picture of LVV than is achievable using current methods.\n\nThe LAVA-FLOW study therefore aims to develop a standardised protocol to be used in different hospital centres across the UK for the imaging of LVV using LAFOV-PET\u002FCT. We also hope that the results of this particular study could lead to further larger studies with the potential to update the diagnostic criteria and improve the monitoring of this condition.",[74,33,75],"Large Vessel Vasculitis","Giant Cell Arteritis (GCA)",[74,77,78,79],"[18F]FDG Long-Axial Field of View (LAFOV)-PET\u002FCT","Angiography","Protocol Optimisation","NOT_YET_RECRUITING","2026-06-01",{"date":83,"type":50},"2026-06-04",{"date":85,"type":20},"2026-07-01",{"date":87,"type":20},"2028-01-01",{"name":89,"class":57},"Imperial College London",3,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":66,"sex":16,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":69,"phases":103,"briefSummary":105,"conditions":106,"keywords":118,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100599701","phase-4-safety-and-immunogenicity-of-the-live-attenuated-tetravalent-butantan-dengue-vaccine-in-autoimmune-rheumatic-diseases-100599701","NCT07087912","Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases","Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine (Butantan-DV) in Patients With Autoimmune Rheumatic Diseases Living in Dengue-Endemic Areas","BTNDV-ARD","Inclusion Criteria:\n\n* Age between 12 and 59 years\n* Male or female\n* Clinical diagnosis of an autoimmune rheumatic disease (ARD) based on internationally accepted criteria (e.g., rheumatoid arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, Sjögren's syndrome, vasculitis)\n* Healthy control matched by age and sex\n* ARD patients with clinically stable disease for at least 3 months\n* ARD patients under low-grade immunosuppression or no immunosuppression\n* Acceptable immunosuppressive treatments include:\n\nHydroxychloroquine Sulfasalazine Prednisone ≤ 20 mg\u002Fday Methotrexate ≤ 0.4 mg\u002Fkg\u002Fweek (maximum 20 mg\u002Fweek) Leflunomide 20 mg\u002Fday Azathioprine \\\u003C 3 mg\u002Fkg\u002Fday Combination therapy with low-dose prednisone (≤ 7.5 mg\u002Fday), hydroxychloroquine, or sulfasalazine\n\n* Healthy controls with no history of autoimmune or chronic infectious diseases\n* Healthy controls not taking immunosuppressive medications Willing and able to comply with study procedures and follow-up\n* Female participants of reproductive potential with negative pregnancy test at baseline\n* Female participants of reproductive potential agreeing to use effective contraception for at least 90 days after vaccination\n\nExclusion Criteria:\n\n* Prior receipt of any dengue vaccine\n* Receipt of a live attenuated vaccine within 4 weeks prior to enrollment\n* Receipt of an inactivated vaccine within 2 weeks prior to enrollment\n* Known allergy to any component of the vaccine\n* Febrile illness (≥ 37.8°C) within 72 hours prior to vaccination\n* History of immunodeficiency syndromes\n* History of asplenia\n* History of cancer\n* History of HIV infection\n* History of primary immunodeficiencies\n* Immunosuppression due to organ transplant\n* Chronic uncontrolled comorbidities (e.g., heart failure, renal failure, hepatic insufficiency, diabetes mellitus)\n* Hospitalization or acute illness at screening\n* Receipt of blood transfusion within 3 months prior to enrollment\n* Current pregnancy or breastfeeding\n* Intention to become pregnant within 90 days post-vaccination\n* Participation in another clinical trial within 30 days prior to enrollment","12 Years","59 Years",{"count":102,"type":20},477,[104],"PHASE4","The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune rheumatic diseases (ARDs) who are clinically stable and under low-grade or no immunosuppression, as well as in healthy volunteers matched by sex and age.\n\nThe main questions it aims to answer are:\n\nDoes the vaccine induce adequate seroconversion in patients with ARDs compared to healthy controls? What is the frequency and intensity of common adverse events after vaccination in ARDs patients? Does physical activity levels and nutritional status influence vaccine-induced immune response in patients with ARDs?\n\nResearchers will compare patients with ARDs to healthy controls to evaluate if the vaccine elicits similar immune responses and safety profiles.\n\nAll participants will:\n\n* receive a single 0.5 mL dose of the Butantan-DV vaccine via subcutaneous injection;\n* undergo blood sample collection before and after vaccination (baseline, Day 42, and Day 400) to assess antibody and cellular responses;\n* attend follow-up visits on Days 7, 14, and 42 for safety monitoring and laboratory tests;\n* report any symptoms or adverse events using a standardized diary for 42 days;\n* be followed for up to one year for long-term safety and immunogenicity assessments.\n* wear a device for 14 consecutive days to assess current and habitual physical activity levels.\n* answer three non-consecutive 24-hour dietary recalls, including at least one weekend day to assess nutritional status.\n* collect blood samples one-year after vaccination to access immunogenicity and cellular response.\n\nResearcher will also perform subgroups analysis in:\n\nA viremia subgroup (50 patients and 50 healthy controls) will provide additional samples on Days 1, 7, 14, 28, 42, and-if viremia is detected-Day 68, to evaluate post-vaccination viremia and its duration.\n\nAn immunogenicity subgroup (\\~20% of participants, n=96) will undergo cellular immune response testing via flow cytometry to evaluate T-cell responses.",[107,108,109,110,111,112,113,114,115,116,117,33],"Rheumatoid Arthritis (RA)","Juvenile Idiopathic Arthritis (JIA)","Systemic Lupus Erythematosus (SLE)","Juvenile Systemic Lupus Erythematosus","Systemic Sclerosis (SSc)","Idiopathic Inflammatory Myopathies (IIMs)","Axial Spondyloarthritis","Psoriatic Arthritis (PsA)","Granulomatosis With Polyangiitis","Microscopic Polyangiitis","Antiphospholipid Syndrome",[119,120,121,122,123,124,125],"Tetravalent Vaccine","Butantan-Dengue Vaccine","Autoimmune Rheumatic Diseases","Rheumatology","Pediatric Rheumatology","Infectious Disease Prevention","Vaccine","2026-04-14",{"date":128,"type":50},"2026-04-15",{"date":130,"type":20},"2026-03-16",{"date":132,"type":20},"2028-12-30",{"name":134,"class":57},"University of Sao Paulo General Hospital",2,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":144,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":69,"phases":147,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100629678","phase-2-phase-ii-interventional-study-evaluating-efficacy-and-safety-of-secukinumab-in-active-severe-takayasu-patients-100629678","NCT07477795","Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients","Prospective, Bayesian, Randomized, Controlled, Open-label, Parallel-group, Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients","STARS","Inclusion Criteria:\n\n1. Patients ≥15 years\n2. Signed informed consent\n3. Affiliation with the French national social security system.\n4. Adequate and effective contraceptive measures based on CTFG update of recommendations version 1.1 dated 21-Sep-2020\n5. For women of childbearing age, a negative serum or urinary pregnancy test.\n6. Diagnosis of TAK based on the 2022 American College of Rheumatology\u002FEULAR and\u002For Ishikawa criteria modified by Sharma (Appendix 1) for patients with age ≥ 18 years and based the PRINTO\u002FEULAR\u002FPReS criteria for patients with age between 15 and 17 years\n7. Active TAK defined by a National Institutes of Health \\[NIH\\] score \\>1 in the past 2 months (Appendix 2)\n8. Severe TAK, defined as either refractory\u002Frelapsing disease or by the presence of severe arterial involvement at baseline.\n\n   1. refractory\u002Frelapsing disease is defined as the recurrence or persistence of vasculitis activity confirmed by a specialized physician despite adequate corticosteroid tapering (i.e., inability to taper corticosteroids below 1mg\u002Fkg\u002Fday within 1 month due to disease activity, or inability to taper corticosteroids below 10mg\u002Fday within 6 months, or inability to discontinue corticosteroids after 1 year of treatment, or relapse of disease during\u002Fafter gradual decrease of corticosteroids therapy) and\u002For immunosuppressive treatment (e.g., azathioprine, methotrexate, mycophenolate mofetil, leflunomide)\n   2. Severe arterial involvement is defined by the presence of stroke, retinopathy, coronary artery stenosis, pulmonary artery stenosis, mesenteric arteries or celiac trunk stenosis, renal artery stenosis or limb ischemia at baseline.\n9. Patients must be eligible to receive prednisone (or equivalent) 10-50 mg daily at baseline. Oral corticosteroids must be at a stable dose for at least 2 weeks prior to the first administration of study drug at Day 0.\n10. Absence of chronic active infections. Patients with a positive TB test may participate in the study if further work up (according to local practice\u002Fguidelines) conclusively establishes that the patient has no evidence of active tuberculosis. If the test result is indeterminate, the investigator may repeat the test once or may proceed directly to perform the work-up for TB as per local procedure. If presence of latent tuberculosis is established then treatment according to local country guidelines must be initiated prior to randomization\n\nExclusion Criteria:\n\n1. Inability to comply with study guidelines or provide informed consent\n2. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human Chorionic Gonadotropin (hCG) laboratory test.\n\n   Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for 6 months after stopping of investigational drug. Highly effective contraception methods include:\n   * Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g., calendar, ovulation, symptotherma), post- ovulation methods) and withdrawal are not acceptable methods of contraception.\n   * Female bilateral tubal ligation, female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or total hysterectomy at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\n   * Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should be the sole partner for that participant.\n   * Use of oral (estrogen and progesterone), injected, or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \\\u003C 1%), for example hormone vaginal ring or transdermal hormone contraception.\n\n   In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.\n\n   Contraception should be used in accordance with locally approved prescribing information of concomitant medications administered.\n\n   Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age-appropriate history of vasomotor symptoms). Women are considered of not child-bearing potential if • they are post-menopausal or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of child-bearing potential If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the informed consent form (ICF).\n\n   Sexually active males, unless they agree to use barrier protection during intercourse with a woman of child-bearing potential, while taking study treatment. As condom use alone has a reported failure rate exceeding 1% per year, it is recommended that female partners of male study participants use a second method of birth control.\n\n   Globally, for all sexually active males, contraception should be used in accordance with the locally approved prescribing information of concomitant medications administeredPregnancy or breastfeeding;\n3. History of severe immunosuppression, positive serology for HIV or positive HBsAg\n4. Infection requiring treatment with intravenous antibiotics within 2 weeks prior to the inclusion \\& randomization visit\n5. Contraindication or hypersensitivity to Secukinumab, TNF inhibitors or tocilizumab, corticosteroids, TB prophylactic treatment or to any of their excipients. For contra-indications related to the standard of care medications refer to the summary of each Product Characteristics (SmPC) refer to EMA links (7.1.2)\n6. Have received live vaccines within 3 months prior to inclusion\n7. Indication to initiate infliximab, adalimumab, tocilizumab, secukinumab for another active disease than Takayasu arteritis (retained)\n8. Use of the following systemic treatments during the specified periods\n\n   1. Treatment with biologic therapy secukinumab, within 3 months prior to the inclusion \\& randomization visit\n   2. Treatment with any systemic alkylating agents within 3 months prior to the inclusion \\& randomization visit (e.g., cyclophosphamide, chlorambucil)\n9. Presence of any of the following on-ongoing and on-treatment disease processes (vasculitis and auto- immunes disease):\n\n   Microscopic polyangiitis\n   * Granulomatosis with polyangiitis Eosinophilic granulomatosis with polyangiitis\n   * Polyarteritis nodosa o Cogan's syndrome\n   * Behcet's disease\n   * Kawasaki's disease\n   * Atypical mycobacterial infections\n   * Deep fungal infections o Lymphoma, lymphomatoid granulomatosis, or other type of malignancy that mimics vasculitis o Cryoglobulinemic vasculitis\n   * Systemic lupus erythematosus\n   * Rheumatoid arthritis o Mixed connective tissue disease or any overlap autoimmune syndrome\n   * Known constitutive immunodeficiency\n10. History of malignancy in the last 5 years (except adequately treated basal or squamous cell carcinoma of the skin)\n11. Severe renal impairment (creatinine clearance \\\u003C30mL\u002Fmin\u002F1.73m2)\n12. History of clinically significant liver disease or liver injury as indicated by abnormal liver function tests such as Aspartate Aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) or serum bilirubin. The investigator should be guided by the following criteria:\n\n    1. SGOT (AST) and SGPT (ALT) may not exceed 3 × the upper limit of normal (ULN). A single parameter elevated up to and including 3 × ULN should be re-checked once more as soon as possible, and in all cases, at least prior to randomization, to rule-out laboratory error.\n    2. Alkaline phosphatase may not exceed 4 × ULN. An elevation up to and including 4 × ULN should be re-checked once more as soon as possible, and in all cases, at least prior to randomization, to rule-out laboratory error.\n    3. Total bilirubin may not exceed 4 × ULN. If the total bilirubin concentration is increased above 4 × ULN, total bilirubin should be differentiated into the direct and indirect reacting bilirubin\n13. Blood count abnormality:\n\n    1. Platelet count \\\u003C 50 x 10.3\u002Fmm3\n    2. Neutropenia \\\u003C 1000\u002Fmm3\n    3. Haemoglobin \\\u003C 8 g\u002Fdl","15 Years",{"count":146,"type":20},52,[148],"PHASE2","Takayasu's arteritis (TAK) is a large vessel vasculitis preferentially affecting the aorta and its main branches, leading to wall vessels thickening, fibrosis, stenosis, and occlusion. Patients with TAK have a high morbidity rate, 50% will relapse and experience a vascular complication within 10 years from diagnosis. TAK inflammation is mediated by T cells and macrophages. Pro-inflammatory Th1 and Th17 cells are dominant infiltrates in the vascular walls, producing IFN-γ and IL-17 to drive the systemic and vascular manifestations of TAK. Currently, TAK patients are principally treated with non-specific steroids, which are associated with potential side effects, especially when used for a long-time course. Steroid treatment preferentially target innate cytokines, such as IL-1β, IL-12, and IL-6 but have little effect on tissue-residing T cells. Novel approach needs to eliminate all T-cell effectors. The use of classical immunosuppressive drugs (IS) (methotrexate, Leflunomide) and biotherapies are prescribed earlier in the management of the disease in order to improve remission, spare corticosteroids and reduce relapses. Data from observational series report remission in 37-76% of cases with anti TNF alpha and 68% with Tocilizumab. However, a placebo-controlled trial failed to show superiority of tocilizumab in TAK.\n\nTo date, no immunomodulatory treatment has been approved for the management of TAK and corticosteroids sparing remains a major challenge in this disease. Our team has demonstrated the key role of Th1 and Th17 responses in the pathophysiology of TAK. We found that Th17 and Th1 pathways contribute to the systemic and vascular manifestations of TAK and glucocorticoid treatment suppresses Th1 cytokines but spares Th17 cytokines in patients with TAK. Other teams further confirmed the significant increase in Th17 axis in TAK, and its correlation with disease activity, clinical relapse and arterial fibrosis. Secukinumab is a fully human monoclonal antibody that selectively inhibits IL-17A. Secukinumab received approval for adult treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, active non-radiographic axial spondyloarthritis, and active ankylosing spondylitis in numerous countries, including the EU and the USA Recently, a phase II clinical trial assessing the efficacy and safety of secukinumab vs placebo in combination with glucocorticoid taper regimen in giant cell arteritis showed that patients with active giant cell arteritis had a higher sustained remission rate in the secukinumab group than in the placebo group at week 28, and is now being studied in a phase 3 study (NCT04930094).Secukinumab was well tolerated with no new safety concerns. In TAK, recent observational data suggested that secukinumab might be an effective alternative to TNFi in severe TAK patients.\n\nInhibition of IL-17A could represent a potential new therapeutic option for the treatment of severe TAK disease, hence the need for a prospective study to evaluate secukinumab in the management of active severe TAK.",[33,74],[152,74],"Takayasu arteritis","2026-03-23",{"date":155,"type":50},"2026-03-27",{"date":157,"type":20},"2026-04-01",{"date":159,"type":20},"2030-04-01",{"name":56,"class":57},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":69,"phases":170,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":58},"100630764","biologic-treatment-withdrawal-in-takayasu-arteritis-patients-in-sustained-remission-100630764","NCT07491913","Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","Cessation of Biologic Treatment in Patients With Takayasu Arteritis in Sustained Remission","Inclusion Criteria:\n\n* Diagnosis of Takayasu arteritis according to the 2022 American College of Rheumatology\u002FEULAR classification criteria\n* Treatment with biologic therapy (TNF inhibitors or tocilizumab) for at least 3 years\n* Sustained clinical, laboratory, and radiologic remission\n* No change in treatment during the previous 12 months\n* No glucocorticoid use within the previous 6 months\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Presence of other active inflammatory diseases requiring biologic therapy (e.g., inflammatory bowel disease, ankylosing spondylitis)\n* Inability to attend scheduled follow-up visits after treatment tapering and discontinuation\n* Pregnancy or planning pregnancy during the study period",{"count":169,"type":20},40,[71],"Takayasu arteritis is a chronic large-vessel vasculitis affecting the aorta and its major branches. Biologic therapies such as tumor necrosis factor inhibitors and tocilizumab are commonly used in patients with refractory or relapsing disease. However, there is limited evidence regarding the optimal duration of biologic therapy and the safety of treatment discontinuation in patients who achieve sustained remission.\n\nThis prospective study aims to evaluate the outcomes of planned biologic treatment withdrawal in patients with Takayasu arteritis who have been in long-standing clinical and radiologic remission and have received biologic therapy for at least three years. Eligible patients will undergo a predefined 3-month dose tapering protocol. Patients who remain relapse-free during this period will discontinue biologic therapy and will be followed for 12 months.\n\nThe primary objective of the study is to determine the proportion of patients who maintain remission after biologic treatment withdrawal. Secondary objectives include evaluating the rate and timing of disease relapse during the tapering phase and the post-withdrawal follow-up period.",[33],[152,174,175,176,177,178],"Biologic therapy withdrawal","Treatment discontinuation","TNF inhibitors","Tocilizumab","Large vessel vasculitis","2026-03-18",{"date":181,"type":50},"2026-03-25",{"date":183,"type":50},"2025-06-15",{"date":185,"type":20},"2027-12-15",{"name":187,"class":57},"Marmara University",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":197,"conditions":198,"keywords":208,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":226},"100283245","vcrc-tissue-repository-100283245","NCT02967068","VCRC Tissue Repository","VCRC Tissue Biorepository Collection Protocol","Inclusion Criteria:\n\n* A participant will be deemed eligible for this study if the participant is\u002Fwas enrolled in another one of the VCRC observational\u002Flongitudinal protocols (5502, 5503, 5504, 5505, 5506, 5507, 5563) and\u002For one of the VCRC interventional studies (5522, 5523, 5526, 5527, or 5562).\n\nExclusion Criteria:\n\n* Inability to give informed consent (or their guardians in the case of children) and to sign the consent form.\n* Unwilling to allow the use of their tissue for research.",{"count":196,"type":20},1000,"The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies. Analysis of these tissue specimens and linked clinical data collected through VCRC studies may lead to the identification and development of a series of translational research projects. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.",[199,200,201,202,203,204,205,116,206,33,207],"Aortitis","Cutaneous Vasculitis","Eosinophilic Granulomatosis With Polyangiitis","Giant Cell Arteritis","Granulomatosis With Polyangiitis (Wegener's)","Henoch-Schonlein Purpura","IgA Vasculitis","Polyarteritis Nodosa","Churg-Strauss Syndrome",[209,210,211,212,213,214,215,216],"CSS","EGPA","GCA","GPA","MPA","PAN","TAK","HSP","2026-01-21",{"date":219,"type":50},"2026-01-22",{"date":221,"type":50},"2016-11",{"date":223,"type":20},"2028-12",{"name":225,"class":57},"University of Pennsylvania",8,{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":66,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":69,"phases":236,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":58},"100584263","phase-2-dapagliflozin-and-endothelin-receptor-antagonism-in-large-vessel-vasculitis-derail-lvv-100584263","NCT06887062","Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)","DERAIL-LVV","Inclusion Criteria:\n\n* A diagnosis of large vessel vasculitis that has been in remission for ≥ 6 months.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Active LVV\n* Any organ transplant recipients\n* A requirement for any medications that are contra-indicated whilst taking Bosentan or dapagliflozin\n* Congestive cardiac failure\n* Patients not medically fit to attend study visits\n* Patients without mental capacity or willingness to provide informed consent\n* History of multiple and\u002For severe (clinical judgement as determined by the Investigator) allergic reactions to drugs, including the study drug, or food\n* Patients who are pregnant or breast feeding, or those who plan to become pregnant during the study\n* Participation in another clinical trial for 28 days before or 90 days after the study period",{"count":235,"type":20},60,[148],"Large vessel vasculitis (LVV) is a disease that causes damage to blood vessels. This damage to blood vessels can increase the risk of patients with LVV developing cardiovascular disease, including heart attacks and strokes. A chemical produced in the body called endothelin may contribute to this increase in cardiovascular disease risk by causing the vessels to stiffen and blood pressure to increase.\n\nIt has previously been shown that by blocking the effects of endothelin, vessel stiffness and blood pressure improve. Bosentan is a tablet that blocks the effects of endothelin.\n\nDapagliflozin is a sodium-glucose co-transporter 2 inhibitor that has been shown to improve blood vessel function and stiffness in patients with diabetes.\n\nThe investigators plan to assess blood vessel function in those with LVV and participants without LVV. Participants with LVV will be given Bosentan and Dapagliflozin for 6 weeks, followed by Dapagliflozin for 4 weeks, to evaluate their impact on blood vessel function.",[74,75,33],[178,152,240,241,242,243,244,245,246,247],"Giant cell arteritis","Endothelin","Bosentan","Inflammation","Endothelial dysfunction","Dual enodthelin receptor antagonism","dapagliflozin","SGLT2 inhibitor","2026-01-12",{"date":250,"type":50},"2026-01-14",{"date":252,"type":50},"2025-03-21",{"date":254,"type":20},"2027-07-01",{"name":256,"class":57},"University of Edinburgh",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":58},"100619961","investigating-management-perspectives-and-attitudes-towards-care-in-takayasu-arteritis-100619961","NCT07351422","Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis","TAK-IMPACT","Inclusion Criteria:\n\nFor the patient questionnaire:\n\n* Age ≥ 18 years\n* A formal diagnosis of TAK\n\nFor the physician questionnaire\n\n• A physician involved in the management\u002Fdecision-making for patients diagnosed with TAK\n\nExclusion Criteria:\n\nFor the patient questionnaire:\n\n* Age \\\u003C 18 years\n* Lack of a formal diagnosis of TAK\n* Patients without mental capacity or willingness to provide informed consent\n* Not UK based\n\nFor the physician questionnaire\n\n* Not involved in the management\u002F decision making for patients diagnosed with TAK\n* Not willing to take part\n* Not UK based",{"count":265,"type":20},50,"This study aims to understand the experiences of patients with Takayasu arteritis (TAK) and how physicians manage the condition. To achieve this, two separate questionnaires will be conducted: one for patients and one for physicians.",[33,268],"Takayasu Arteritis (TAK)","2026-01-09",{"date":271,"type":50},"2026-01-20",{"date":273,"type":50},"2025-10-01",{"date":275,"type":20},"2027-03-15",{"name":256,"class":57},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":69,"phases":287,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":4},"100617956","phase-4-effect-of-pirfenidone-on-ta-fibrosis-100617956","NCT07325357","Effect of Pirfenidone on TA Fibrosis","A Single-center, Randomized, Double-blind, Controlled Study Comparing the Efficacy and Safety of Pirfenidone Versus Placebo in the Treatment of Takayasu Arteritis on the Basis of Conventional Immunosuppressive Therapy","Inclusion Criteria:\n\n1. Patients who have signed the informed consents and meet the ACR 2022 classification criteria for Takayasu arteritis.\n2. Male or female, age between 18 and 60 years.\n3. Female patients must have a negative serum or urine pregnancy test and do not have pregnancy plans during the study period.\n4. Within the 3 months prior to enrollment, the patient's treatment regimen must consist of glucocorticoids and immunosuppressants (methotrexate). Biological agents (IL-6R, TNF, or monoclonal antibody) might be used based on clinical need. Other targeted therapies (such as CD20 monoclonal antibodies, JAK inhibitors, etc.) or cell-based therapies (such as CAR-T or stem cell therapy) are not permitted.\n5. During the 6-month follow-up period, the dosage and frequency of existing methotrexate and biologics (IL-6R monoclonal antibody, TNF monoclonal antibody, IL17 monoclonal antibody) must remain unchanged, except for adjustments of glucocorticoid doses based on clinical condition.\n6. After 3 months of the above combination glucocorticoid and immunosuppressants, patients must achieve remission of disease activity (NIH score \\\u003C2) and meet at least 3 of the following 5 criteria:\n\n   i. Thickening of the affected vessel wall accompanied by luminal stenosis validated by angiographic examination.\n\nii. Carotid ultrasound showing medium-to-high echogenicity of the carotid artery wall.\n\niii. Progression in the thickness of the affected arterial wall compared to previous 3 months, with or without progression of luminal stenosis.\n\niv. Improvement in the thickness of the affected arterial wall of \\\u003C10% compared to previous 3 months.\n\nv. Within the 3 months prior to enrollment, the occurrence of new vascular ischemic symptoms or ischemic events, or worsening of pre-existing vascular ischemic symptoms. The ischemic symptoms or events must meet at least one of the criteria listed in the table below: Category (Criterion) Vascular Ischemic Signs\n\n1. New emerged vascular bruits (carotid, subclavian, or renal arteries).\n2. Newly emerged absent pulses (carotid, subclavian, brachial, radial, femoral, or dorsalis pedis arteries).\n3. New emerged systolic blood pressure difference ≥10 mmHg between left and right arms.\n4. New emerged systolic blood pressure difference ≥30 mmHg between ipsilateral upper and lower limbs.\n5. Intermittent claudication in upper or lower limbs.\n\nCardiac\n\n1. For non-hypertensive patients, blood pressure elevation to \\>140\u002F90 mmHg.\n2. For hypertensive patients, an increase in diastolic blood pressure ≥20 mmHg from baseline.\n3. Ischemic angina.\n4. Myocardial infarction.\n5. Aortic valve insufficiency (moderate or severe).\n\nCerebral\n\n1. Ischemic stroke.\n2. New emerged ischemic symptoms: syncope, visual or auditory abnormalities such as decreased vision, visual field defects, etc.\n3. CT cerebral perfusion imaging indicating ischemic or infarcted areas (with a corresponding volume \\>10 ml detected by CTP software).\n\nRenal Radionuclide renogram showing a decrease in glomerular filtration rate over 10%; or an increase in serum creatinine exceeding 50% compared with the baseline.\n\nExclusion Criteria:\n\n1. Presence of autoimmune diseases or autoinflammatory diseases other than Takayasu arteritis (e.g., systemic lupus erythematosus, ankylosing spondylitis, rheumatoid arthritis, etc.);\n2. Use of antifibrotic drugs or drugs with potential antifibrotic properties (such as acetylcysteine, nintedanib, pirfenidone, etc.) within 6 months prior to enrollment, or participation in other clinical trials involving antifibrotic therapies;\n3. Impaired liver function (elevated transaminases ALT\u002FAST \\>2 times the upper limit of normal, or bilirubin exceeding the upper limit of normal), severe renal insufficiency (eGFR \\\u003C15 mL\u002Fmin\u002F1.73m²), or requirement for psychotropic medications (excluding sleep medicine for sleep disorders);\n4. Any severe, progressive, or uncontrolled concurrent hematological, gastrointestinal, pulmonary, cardiac, neurological, or other medical conditions unrelated to Takayasu arteritis which could pose unpredictable risks, in the investigator's judgment;\n5. Allergy to the investigational drug or previous failure of regular pirfenidone treatment for 3 months;\n6. Due to pirfenidone's metabolism primarily via cytochrome P450 isoenzymes (particularly CYP1A2), use of CYP1A2 inducers or inhibitors prior to enrollment must be discontinued and avoided throughout the study period; such medications are also prohibited during the study unless deemed medically necessary by the investigator for managing adverse events;\n7. History of allergy to MRA contrast agents;\n8. Planned vascular surgery during the 6-month follow-up period which may interfere with assessment results.\n\nCYP1A2 Inhibitors:\n\nAcyclovir, amiodarone, atazanavir, caffeine, cimetidine, ciprofloxacin, enoxacin, famotidine, flutamide, fluvoxamine, lidocaine, lomefloxacin, mexiletine, moclobemide, norfloxacin, ofloxacin, perphenazine, propafenone, ropinirole, tacrine, ticlopidine, tocainide, verapamil\n\nCYP1A2 Inducers:\n\nCarbamazepine, esomeprazole, griseofulvin, lansoprazole, moricizine, omeprazole, rifampin, ritonavir","60 Years",{"count":286,"type":20},92,[104],"Takayasu arteritis is a severe vasculitis which could lead to significant disability and even death. While standard anti-inflammatory treatments can manage the systemic inflammation, they failed to stop a key driver of the disease: vascular fibrosis. This fibrosis could result in blood vessels thickening and narrowing, which continues to progress in many patients.\n\nTo tackle this critical treatment gap, the present project explores a new strategy. Building on pirfenidone's success in treating fibrosis in organs just like lungs and liver, along with promising early observations from our center, investigators believe adding this anti-fibrotic drug to standard therapy could improve vessel injury directly.\n\nTherefore, investigators plan to conduct a clinical trial comparing pirfenidone with placebo in patients with Takayasu arteritis. The goal is to determine if this approach can successfully improve vascular injury and patient outcomes ultimately.",[33],[291,292,293,152],"fibrosis","pirfenidone","inflammation","2026-01-07",{"date":296,"type":50},"2026-01-08",{"date":298,"type":20},"2025-12-20",{"date":300,"type":20},"2030-12-31",{"name":302,"class":57},"Shanghai Zhongshan Hospital",{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":66,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":311,"conditions":312,"keywords":315,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":58},"100614168","physical-and-psychosocial-parameters-in-takayasu-arteritis-and-behets-disease-a-comparative-study-with-healthy-controls-100614168","NCT07276087","Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy Controls","Inclusion Criteria:\n\nInclusion Criteria (Takayasu Arteritis Group):\n\n* Age 18 years or older.\n* Diagnosis of Takayasu arteritis according to the American College of Rheumatology (ACR) classification criteria.\n* Voluntary participation with written informed consent.\n\nInclusion Criteria (Behçet's Disease Group):\n\n* Age 18 years or older.\n* Diagnosis of Behçet's disease according to the International Study Group for Behçet's Disease criteria.\n* Voluntary participation with written informed consent.\n\nInclusion Criteria (Healthy Control Group):\n\n* Age 18 years or older.\n* No history of systemic, rheumatologic, or chronic inflammatory disease.\n* Voluntary participation with written informed consent.\n\nExclusion Criteria:\n\nExclusion Criteria (Patient Groups - Takayasu Arteritis and Behçet's Disease):\n\n* Pregnancy.\n* Presence of psychiatric disorder or ongoing psychiatric treatment.\n* Cognitive impairment that may interfere with participation.\n* Presence of neurological disease (e.g., hemiplegia, Parkinson's disease, multiple sclerosis, vertigo, epilepsy, etc.).\n* History of any surgical operation within the past year.\n* Coexisting rheumatic disease other than Takayasu arteritis or Behçet's disease.\n\nExclusion Criteria (Healthy Control Group):\n\n* Pregnancy.\n* Presence of psychiatric disorder or ongoing psychiatric treatment.\n* Cognitive impairment that may interfere with participation.\n* Presence of neurological disease (e.g., hemiplegia, Parkinson's disease, multiple sclerosis, vertigo, epilepsy, etc.).\n* History of any surgical operation within the past year.\n* History of rheumatologic or chronic inflammatory disease.",{"count":310,"type":20},30,"Systemic vasculitis refers to a group of rare diseases characterized by inflammation of blood vessel walls, which may cause ischemia and structural damage in various organs. Among large-vessel vasculitides, Takayasu arteritis primarily affects the aorta and its main branches, whereas Behçet's disease is a variable vessel vasculitis involving arteries and veins of all sizes. Both conditions can lead to multisystemic involvement and significantly impact physical and psychosocial health.\n\nThis observational, case-control study aims to compare multiple physical and psychosocial parameters among individuals with Takayasu arteritis, Behçet's disease, and healthy controls. Assessments will include respiratory and peripheral muscle strength, functional status, exercise capacity, body composition, quality of life, illness perception, and psychological well-being. Measurements will be conducted using standardized clinical tests (such as maximal inspiratory and expiratory pressures, handgrip and limb strength dynamometry, squat test, and six-minute walk test) and validated questionnaires (Health Assessment Questionnaire (HAQ), the Short Form-36 Health Survey (SF-36), the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L), and the Visual Analogue Scale (VAS)).\n\nThe study seeks to identify differences between groups and provide a comprehensive understanding of how systemic inflammation in Takayasu arteritis and Behçet's disease affects physical performance, quality of life, and psychosocial health. These findings may help guide physiotherapy, rehabilitation, and multidisciplinary management strategies for patients with systemic vasculitis.",[33,313,314],"Behçet's Disease","Healthy Controls",[152,316,317,318],"Behçet's disease","Systemic vasculitis","Muscle strength","2025-12-09",{"date":321,"type":50},"2025-12-10",{"date":323,"type":50},"2025-09-11",{"date":325,"type":20},"2026-01-30",{"name":327,"class":57},"ÖZLEM NUR TOK YAMAN",{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":338,"conditions":339,"keywords":345,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":364},"100508736","armenian-nationwide-registry-of-systemic-autoimmune-and-autoinflammatory-diseases-100508736","NCT05904301","Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases","Armenian Nationwide Registry of Systemic Autoimmune and Autoinflammatory Diseases","NAREG","Inclusion Criteria:\n\n1. Patients with a confirmed diagnosis of at least one of following autoimmune systemic diseases:\n\n   Behcet disease, ANCA -positive vasculitis, Takayasu arteritis, Giant cell arteritis, Systemic sclerosis, Sjogren syndrome, Rheumatoid arthritis, Spondylarthritis (psoriatic, ankylosing, crohn's related), Angioedema hereditary and acquired, Pediatric dermatology, Autoinflammatory diseases (hereditary and acquired), Unexplained infertility, Immune thrombocytopenic purpura\u002F Autoimmune hemolytic anemia (ITP, AHA), Primary anti-phospholipid syndrome (APS), Celiac disease.\n2. Age: major and minor\n3. Patients who have been informed and provided with written informed consent to participate Or consent from legal representative\n\nExclusion Criteria:\n\n1. Patients refusing to participate in the registry\n2. Non-consent from legal representative\n3. Breastfeeding or pregnant patients",{"count":337,"type":20},800,"Longitudinal prospective multicenter Armenian registry of systemic autoimmune, autoinflammatory diseases with constitution of bio-banking.",[32,340,33,202,341,30,342,343,344],"Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis","Sjogren's Syndrome","Hereditary and Acquired Angioedema","Primary Antiphospholipid Syndrome","Celiac Disease",[346,347,348,349,350,351,352,353,354],"arthritis","autoimmune","systemic","autoinflammatory","Behcet","Takayasu","Giant Cell","Angioedema","APS","2025-04-04",{"date":357,"type":50},"2025-04-08",{"date":359,"type":50},"2023-06-21",{"date":361,"type":20},"2028-06-30",{"name":363,"class":57},"Santé Arménie French-Armenian Research Center",6,{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":371,"enrollmentInfo":372,"targetDuration":4,"studyType":69,"phases":374,"briefSummary":375,"conditions":376,"keywords":377,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":58},"100554361","phase-4-a-randomized-controlled-open-label-multicenter-clinical-trial-comparing-the-efficacy-and-safety-of-a-precision-treatment-regimen-based-on-clinical-molecular-phenotypes-with-a-conventional-treatment-regimen-in-the-treatment-of-patients-with-active-takayasus-arteritis-100554361","NCT06498089","A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis","Inclusion Criteria:\n\n1\\) Meet the 2022 ACR\u002FEULAR classification criteria for aortitis; 2) Women or men aged 18-65 years; 4) Be in active disease: a National Institutes of Health (NIH) score of ≥2; 5) Females with negative serum or urine pregnancy test results and no plans to have children during the clinical trial; (6) If the patient is taking prednisone or its equivalent, the pre-enrolment dose does not exceed 0.6 mg\u002Fkg\u002Fday and the dose has been stable for at least 4 weeks; 7) If the patient is receiving other medications for aortitis that are inconsistent with the assigned regimen, discontinuation is required for ≥4 weeks for methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, and tacrolimus; for leflunomide, discontinuation is required for 11 days if elimination methods are used (kolexanil or activated charcoal), or ≥8 weeks if elimination is not used; for cyclophosphamide, discontinuation is required for ≥6 months; for biologics, stopping for ≥ 3 weeks is required for etanercept, ≥ 4 weeks for IL-6 receptor antagonists and tumour necrosis factor inhibitors, and ≥ 6 months for rituximab.\n\n8)For patients with no obvious active tuberculosis lesions but elevated T-spot, it is recommended that infectious specialists evaluate them, and preventive anti-tuberculosis therapy should be performed first if necessary. After T-spot declines, researchers will assess the relevant risks before deciding whether they are suitable to participate in this study, and continue preventive anti-tuberculosis therapy for a total of 9 months.\n\n9)For patients with HBV, if the viral replication was detected, it is recommended to take anti-viral treatment for 2-4 weeks, and researchers will evaluate whether they are suitable to participate in this study when no DNA replication is detected.\n\nExclusion Criteria:\n\n1. Presence of organ failure;\n2. undergoing haemodialysis or major surgery (grade III and above) within 3 months;\n3. the presence of other autoimmune diseases;\n4. severe, progressive organ damage;\n5. Subjects with other comorbidities that may result in the need for additional moderate to high doses of glucocorticoids (prednisone ≥ 10 mg\u002Fday or equivalent doses of prednisone equivalents) during the study period;\n6. Have a history of malignancy;\n7. Have any serious acute or chronic infection, including hepatitis B surface antigen positive, active tuberculosis.","65 Years",{"count":373,"type":20},124,[104],"This study aimed to compare the efficacy and safety of a precision treatment regimen based on clinical-molecular phenotypes with a conventional treatment regimen in the treatment of patients with active Takayasu's arteritis based on a randomized, controlled, open-label, multicenter study.",[33],[378,379],"Precise treatment","Clinical-molecular phenotype","2024-10-15",{"date":382,"type":50},"2024-10-17",{"date":384,"type":50},"2024-06-28",{"date":386,"type":20},"2027-06-30",{"name":302,"class":57},{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":371,"enrollmentInfo":395,"targetDuration":4,"studyType":69,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":58},"100447131","phase-4-comparison-of-tofacitinib-and-methotrexate-in-takayasus-arteritis-100447131","NCT05102448","Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis","Comparison of the Efficacy and Safety of Tofacitinib and Methotrexate Based on Prednisone Therapy in Patients with Active Phase of Takayasu's Arteritis: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients met 1990 American College of Rheumatology (ACR) classification criteria or 2018 ACR classification criteria (draft) of TAK\n2. Women or men aged 18-65\n3. All patients agreed that there is no fertility plan during clinical trials, and the results of female serum or urinary pregnancy tests must be negative\n4. Active TAK patients according to NIH disease activity criteria\n5. All patients agreed to sign the informed consent\n\nExclusion Criteria:\n\n1. Patients with organ failure who accord to one or more of the following conditions:\n\n   I.Heart function New York class 4 II.Glomerular filtration rate ≤ 60ml\u002Fmin III.Liver function Child grade 2 and above IV.High-frequency melanoma (attacks for 3 consecutive days) V.Acute cerebral infarction or cerebral hemorrhage VI.Blood pressure \\> 160\u002F100mmHg\n2. Patients who received revascularization surgery related to the treatment of TAK within 3 months (except balloon dilatation); balloon dilatation or surgery unrelated to TAK within 1 month\n3. Patients who have other autoimmune diseases (e.g. ANCA-associated vasculitis, systemic lupus erythematosus, Behcet's disease, etc.)\n4. Patients with severe, progressive or uncontrolled comorbidities of kidney, liver, blood system, gastrointestinal, lung, heart, etc or other coexisting medical conditions that may exert unexpected risks\n5. Patients with concomitant diseases, such as asthma, that may require additional medium to high doses of glucocorticoids (prednisone ≥ 10mg\u002F days or equivalent dose) during the study period\n6. Patients with active infections with HBV, HCV, tuberculosis or other serious acute or chronic infections\n7. Patients with malignancies\n8. Patients with one or more of the following abnormal laboratory examinations I.Serum ALT or AST ≥ 1.5 times the normal upper limit; II.White blood cell count ≤ 4 × 109\u002FL III.Platelet count ≤ 100x109\u002FL IV.Hemoglobin \\\u003C 85g\u002FL V.Other abnormal laboratory tests that may cause unacceptable risks\n9. Patients allergic to the experimental drug\n10. Patients who have ever failed to tofacitinib or methotrexate after 3 months' treatment in previous medical history",{"count":396,"type":20},76,[104],"The aim of this study is to evaluate and compare the efficacy and safety of tofacitinib and methotrexate based on prednisone therapy in patients with Takayasu arteritis",[33],"2024-10-09",{"date":380,"type":50},{"date":403,"type":50},"2021-11-01",{"date":405,"type":20},"2025-12-31",{"name":302,"class":57},{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":371,"enrollmentInfo":415,"targetDuration":4,"studyType":69,"phases":417,"briefSummary":418,"conditions":419,"keywords":421,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":58},"100529795","remote-ischemic-conditioning-for-cerebral-ischemia-in-patients-with-takayasu-arteritis-taric-1-100529795","NCT06178419","Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1)","Safety and Efficacy of Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis: a Prospective Cohort Study","TARIC-1","Inclusion Criteria:\n\n* All patients fulfilled the 1990 American College of Rheumatology Classification Criteria for TAK\n* Inactive state\n* Male and female, aged 18-65 years old\n* The presence of supra-aortic vascular involvement ( including but not limited to the left and right sides of the common carotid artery, subclavian artery, vertebral artery involvement )\n* Decreased cerebral blood perfusion in the whole brain ( compared with healthy people ) or local ( left and right brain contrast ) suggested by pseudo-Continuous arterial spin labeling ( pCASL ) -MRI\n* Voluntary participation in this study, signed informed consent\n\nExclusion Criteria:\n\n* Complications that endanger the function of important organs, such as uncontrollable heart failure, severe heart valve disease, severe hypertension, severe myocardial ischemia, pulmonary hypertension, acute cerebral infarction, arterial dissection or aneurysm rupture, etc\n* There are serious complications, such as poorly controlled diabetes, renal insufficiency, cardiopulmonary insufficiency, mental illness or malignant tumor\n* There were moderate to severe stenosis of brachial artery in both upper limbs",{"count":416,"type":20},44,[71],"The aim of this study is to evaluate the safety and efficacy of remote ischemic conditioning ( RIC ) in the protection of cerebral ischemia in patients with Takayasu arteritis ( TAK ). The study was designed as a prospective, double-blind, exploratory randomized controlled study. The entire study included a screening period and a treatment observation period ( a total of 24 weeks ). All patients with cerebral ischemia of TAK will be randomly divided into RIC group and sham RIC group at 1:1 ratio. On the basis of receiving the conventional drug therapy, the patients will be treated with RIC or sham RIC treatment twice daily for six month. The clinical data of patients at baseline and each follow-up will be collected, including basic information, disease activity assessment, laboratory indicators, imaging indicators, treatment data, adverse events, etc.The Primary outcome is the mean cerebral blood flow improvement rate ( mCBF-IR ) of TAK patients after 24 weeks-treatment. Secondary endpoints include the incidence of major adverse cerebrovascular events ( MACE ) , the change value of arterial transit time ( ATT ) in pCASL hypoperfusion area compared with baseline, occurrence of RIC-related adverse reactions, the changes of hematological indexes and disease activity score, etc. This study will provide insights into the preliminary proof of principle, safety, and efficacy of RIC in cerebral ischemia in patients with Takayasu arteritis ( TAK ), and this data will provide parameters for future larger scale clinical trials if efficacious.",[420,33],"Cerebral Ischemia",[420,33,422],"remote ischemic conditioning","2024-09-12",{"date":425,"type":50},"2024-09-19",{"date":427,"type":50},"2024-01-01",{"date":429,"type":20},"2025-07-31",{"name":431,"class":57},"Xuanwu Hospital, Beijing",{"id":433,"slug":434,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":16,"minAge":439,"maxAge":440,"enrollmentInfo":441,"targetDuration":4,"studyType":69,"phases":442,"briefSummary":443,"conditions":444,"keywords":447,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":58},"100385590","phase-4-a-pilot-study-in-severe-patients-with-takayasu-arteritis-100385590","NCT04300686","A Pilot Study in Severe Patients With Takayasu Arteritis.","A Pilot Study in the Treatment of Severe Patients With Takayasu Arteritis With Tocilizumab and Adalimumab, Based on ECTA Cohort","Inclusion Criteria:\n\n1. age≥14 years old;\n2. active: Kerr score≥ 2;\n3. severe:\n\n   1. Blood pressure \\> 180\u002F110mmHg;\n   2. ≥ 3 branches with the stenotic rate \\> 70% involved;\n   3. high degree of organ insufficiency: NYHF III\\~IV; eGFR (MRDR) 15\\~ 60ml\u002Fmin;\n\nExclusion Criteria:\n\n1. Severe organ insufficiency;\n2. Acute or chronic active infections including tuberculosis, hepatitis virus, etc.;\n3. Other autoimmune diseases including systemic lupus erythematosus, Behcet disease, IgG4 relative disease;\n4. malignant tumors;\n5. history of severe drug allergy;\n6. successive twice relapse occurs even after the intervention adjustment ( for the benefits of patients)","14 Years","100 Years",{"count":169,"type":20},[104],"Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe. And the biological agents tocilizumab and adalimumab are randomly prescribed in severe patients, to find out the relatively better treatment strategy, facilitating better intervention strategy in severe TAK patients.",[33,177,445,446],"Adalimumab","Treatment",[33,177,445,448],"treatment","2021-08-07",{"date":451,"type":50},"2021-08-10",{"date":453,"type":50},"2020-03-01",{"date":455,"type":20},"2023-12-31",{"name":302,"class":57},{"id":458,"slug":459,"hasResults":11,"nctId":460,"briefTitle":461,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":11,"sex":16,"minAge":463,"maxAge":464,"enrollmentInfo":465,"targetDuration":466,"studyType":21,"phases":4,"briefSummary":467,"conditions":468,"keywords":470,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":58},"100283038","china-takayasu-arteritis-registry-cta-registry-100283038","NCT02964364","China Takayasu Arteritis Registry (CTA Registry)","Inclusion Criteria:\n\n* Age at disease onset \\\u003C 40 years. (Development of symptoms or findings related to Takayasu arteritis at age \\\u003C40 years)\n* Claudication of extremities. (Development and worsening of fatigue and discomfort in muscles of 1 or more extremity while in use, especially the upper extremities)\n* Decreased brachial artery pulse. (Decreased pulsation of 1 or both brachial arteries)\n* BP difference \\>10 mm Hg. (Difference of \\>10 mm Hg in systolic blood pressure between arms)\n* Bruit audible on auscultation over 1 or both subclavian arteries or abdominal aorta.\n* Arteriogram abnormality. (Arteriographic narrowing or occlusion of the entire aorta, its primary branches, or large arteries in the proximal upper or lower extremities, not due to arteriosclerosis, fibromuscular dysplasia, or similar causes; changes usually focal or segmental)\n\nExclusion Criteria:\n\n* Vessel lesions that could be entirely due to atherosclerosis.\n* Giant cell arteritis or other infectious forms of large vessel vasculitis.","5 Years","80 Years",{"count":196,"type":20},"10 Years","Takayasu arteritis (TA) is a chronic large-vessel vasculitis that mainly affects the aorta and its major branches. The epidemiology and pathophysiology of TA is still unclear in China, although many studies have been done. Our previous study supporting by National Natural Science Foundation of China indicated the cytokines such as hs-CRP, NT-proBNP and tumor necrosis factor-alpha (TNF-α) can be used to monitor TA activity, and HLA gene alleles were associated with TA in Chinese han population. Further investigations with larger samples are needed to fully understand the a pathophysiology of TA. The purpose of this study is to build a Chinese national registry system for TA to obtain real-world information, such as current status of characteristics, diagnosis, disease activity, the severity of disease, treatment and outcomes of Chinese TA patients. To analysis and development of effective disease monitoring and treatment strategies.",[469],"TAKAYASU ARTERITIS",[469],"2016-11-13",{"date":473,"type":20},"2016-11-16",{"date":475,"type":4},"2016-08",{"date":477,"type":20},"2026-07",{"name":479,"class":57},"Aimin Dang"]